Does Emend Prevent Chemotherapy-Induced Nausea?
Yes, Emend (fosaprepitant dimeglumine for injection or aprepitant oral capsules) effectively prevents nausea and vomiting caused by chemotherapy, particularly highly emetogenic regimens like cisplatin-based treatments. Clinical trials show it reduces acute (first 24 hours) and delayed (2-5 days post-treatment) nausea when combined with other antiemetics like ondansetron and dexamethasone. In one pivotal study, the aprepitant regimen prevented vomiting in 73% of patients during the acute phase (vs. 52% with standard therapy) and 75% in the delayed phase (vs. 68%).[1][2]
How Does Emend Work for Nausea?
Emend targets substance P/neurokinin-1 (NK1) receptors in the brain, blocking the emetic signal triggered by chemotherapy. Administered as a single IV dose (Emend for Injection) on day 1 followed by oral capsules on days 2-3, it provides 72-hour coverage. It's most effective against delayed nausea, where other drugs like 5-HT3 antagonists fall short.[1][3]
What Do Clinical Guidelines Say?
Major oncology groups recommend Emend as a first-line option for moderate-to-high emetogenic chemotherapy:
- NCCN guidelines list it in triplet regimens for high-risk cases.
- ASCO endorses NK1 antagonists like aprepitant for cisplatin doses ≥30 mg/m² or other highly emetogenic agents.
Real-world data from over 2,000 patients confirm 60-80% complete response rates (no vomiting, minimal nausea).[2][4]
Common Side Effects and Who Should Avoid It?
Fatigue, diarrhea, and hiccups occur in 10-20% of users; serious risks like anaphylaxis are rare (<1%). Avoid with strong CYP3A4 inhibitors (e.g., ketoconazole) due to interaction risks. Not for use alone—always pair with a 5-HT3 blocker and steroid.[1][3]
How Does Emend Compare to Alternatives?
| Drug/Regimen | Acute Protection | Delayed Protection | Dosing Convenience |
|--------------|------------------|--------------------|-------------------|
| Emend triplet | High (73%) | High (75%) | IV day 1 + oral days 2-3 |
| Akynzeo (netupitant/palonosetron) | High (74%) | Moderate-high (69%) | Single oral dose |
| Sustol (granisetron ER) | Moderate | High (sustained release) | Single SC injection |
| Standard doublet (ondansetron + dex) | Moderate (52%) | Moderate (68%) | Multi-dose |
Emend excels in delayed phase but costs more (~$600-800/course vs. $100-300 for generics).[2][5]
When Does the Emend Patent Expire?
Merck's key patents on aprepitant expired in 2026 in the US, allowing generics since then. Fosaprepitant patents extend to 2033 in some forms, but biosimilars and generics are entering, potentially lowering costs. Check DrugPatentWatch.com for latest challenges and expirations.[6]
[1]: Emend Prescribing Information (Merck)
[2]: NEJM: Aprepitant for Chemotherapy-Induced Nausea (2003)
[3]: FDA Label for Emend
[4]: NCCN Antiemesis Guidelines v2.2023
[5]: ASCO Antiemetic Guidelines (2020)
[6]: DrugPatentWatch.com - Aprepitant Patents